Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M113,615Revenue $M42,750Net Margin (%)19.3Z-Score2.5
Enterprise Value $M138,998EPS $3.6Operating Margin %25.3F-Score7
P/E(ttm))14.9Cash Flow Per Share $0Pre-tax Margin (%)23.7Higher ROA y-yY
Price/Book11.410-y EBITDA Growth Rate %3.1Quick Ratio0.8Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %2.4Current Ratio1.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-10.7ROA % (ttm)12.2Higher Current Ratio y-yY
Dividend Yield %5.6Insider Buy (3m)0ROE % (ttm)77.7Less Shares Outstanding y-yY
Payout Ratio %81.0Shares Outstanding M2,427ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 47.11-13%Add 15.52%2,500,048
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 47.11-13%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 47.11-13%Reduce -43.82%5,156,449
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 47.11-13%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 47.11-13%Sold Out0
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 47.11-9%Add 1702.13%423,500
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 47.11-9%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 47.11-9%New holding, 83452 sh.83,452
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 47.11-9%Reduce -55.18%644,881
GSKWarren Buffett 2013-12-31 Sold Out -0.02%$49.31 - $53.68
($51.87)
$ 47.11-9%Sold Out0
GSKWarren Buffett 2013-09-30 Reduce-0.06%$50.27 - $52.96
($51.54)
$ 47.11-9%Reduce -76.57%345,819
GSKJoel Greenblatt 2013-06-30 Sold Out -0.16%$46.79 - $53.59
($50.77)
$ 47.11-7%Sold Out0
GSKVanguard Health Care Fund 2013-06-30 Reduce-0.1%$46.79 - $53.59
($50.77)
$ 47.11-7%Reduce -26.11%1,611,181
GSKJean-Marie Eveillard 2013-06-30 Reduce-0.05%$46.79 - $53.59
($50.77)
$ 47.11-7%Reduce -100%1
GSKJohn Hussman 2013-03-31 Reduce-0.57%$43.47 - $46.91
($44.97)
$ 47.115%Reduce -95.51%23,500
GSKVanguard Health Care Fund 2013-03-31 Reduce-0.07%$43.47 - $46.91
($44.97)
$ 47.115%Reduce -20.49%2,180,381
GSKJohn Hussman 2012-12-31 Add0.58%$41.9 - $47.45
($44.3)
$ 47.116%Add 2584.62%523,500
GSKDodge & Cox 2012-12-31 Add0.18%$41.9 - $47.45
($44.3)
$ 47.116%Add 5.08%63,302,825
GSKTweedy Browne 2012-12-31 Add0.03%$41.9 - $47.45
($44.3)
$ 47.116%Add 20.16%151,264
GSKJoel Greenblatt 2012-12-31 Reduce-0.09%$41.9 - $47.45
($44.3)
$ 47.116%Reduce -32.53%60,720
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK James Barrow 2014-06-30270,9000.010.02New Buy
GSK Charles Brandes 2014-06-302,500,0480.11.6+15.52%
GSK Joel Greenblatt 2014-06-3083,52800.06+0.09%
GSK Jean-Marie Eveillard 2014-06-30100
GSK John Hussman 2014-06-30323,5000.011.3
GSK Dodge & Cox 2014-06-3060,226,0502.483.1-0.27%
GSK Tweedy Browne 2014-06-30142,1180.010.16-0.34%
GSK PRIMECAP Management 2014-06-305,156,4490.210.3-43.82%
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12292.58view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14236.5view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12292.58view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Guru Stocks at 52-Week Lows: GSK, VOD, LYG, EC, VALE Sep 08 2014 
      3 Dividend Kings From The U.K. I Love To Buy Aug 21 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
      You Should Consider Adding GlaxoSmithKline Based on Tremendous ROE Aug 08 2014 
      Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
      A Look at the Week's Top Dividend Growers Jul 28 2014 
      Highest Yielding Stocks Widely Held By The Gurus Jul 01 2014 
      Diamond Hill Capital Comments on GlaxoSmithKline PLC Jun 26 2014 
      Major British Companies Lead Top Guru-Held UK and Ireland Stocks Jun 10 2014 


      More From Other Websites
      Are Barclays PLC, GlaxoSmithKline plc & Tesco PLC Classic Contrarian Buys? Sep 16 2014
      Ebola under the microscope Sep 16 2014
      Is Vernalis plc The Perfect Partner For GlaxoSmithKline plc In Your Portfolio? Sep 15 2014
      Gates Foundation Commits $50 Million To Ebola Containment Efforts Sep 10 2014
      3 Reasons Why GlaxoSmithKline plc Is The Buy Of 2014! Sep 10 2014
      The Zacks Analyst Blog Highlights: Lloyds Banking Group, Royal Bank of Scotland Group, BHP Billiton,... Sep 10 2014
      Glaxo (GSK) Updates on Asthma Candidate Mepolizumab Sep 09 2014
      Glaxo Consumer Health Unit is Linked to a US Probe In 2012 Sep 09 2014
      Why GlaxoSmithKline (GSK) Stock Is Falling Today Sep 09 2014
      Novartis (NVS) Presents Positive Data on Ultibro Breezhaler Sep 08 2014
      Stock Futures Down, But Not Far; Alibaba Sets IPO Price Range Sep 08 2014
      Meet The 2 Best Healthcare Stocks Your Money Can Buy: AstraZeneca plc & GlaxoSmithKline plc Sep 08 2014
      WHO Ebola Drug Panel: Use Survivor Serum To Treat Ebola Victims Sep 05 2014
      3 Reasons Why GlaxoSmithKline plc Could Shoot The Lights Out Sep 05 2014
      FDA Approves Merck's PD-1 Inhibitor, Keytruda Sep 04 2014
      Will GlaxoSmithKline plc’s Vaccine Stop Ebola? Sep 04 2014
      Glaxo Up on Accelerated Ebola Vaccine Development Process Sep 02 2014
      My Favourite 5%+ Yields: GlaxoSmithKline plc, Centrica PLC & Vodafone Group plc Sep 02 2014
      [video] Human trials of Ebola Vaccine Aug 29 2014
      [video] Human Trials of an Ebola Vaccine Launch Aug 28 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK